Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Κύριοι συγγραφείς: Qiao Liu (Συγγραφέας), Zhen Zhou (Συγγραφέας), Xia Luo (Συγγραφέας), Lidan Yi (Συγγραφέας), Liubao Peng (Συγγραφέας), Xiaomin Wan (Συγγραφέας), Chongqing Tan (Συγγραφέας), Xiaohui Zeng (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...